非常规 T 细胞在泌尿系统肿瘤中:能抓住就抓住
Unconventional T cells in urological cancers: catch them if you can.
这些非常规T细胞亚群为新的诊断和治疗策略提供了基础。
DISEASE HUB
FOR TREATMENT
按「中国试验优先 → 正在招募 → 更新更近」排序。信息来自 ClinicalTrials.gov 与 CDE 公开登记。能否入组、费用与可及性,以登记原文和主治医生判断为准。
FOR RESEARCH
Unconventional T cells in urological cancers: catch them if you can.
这些非常规T细胞亚群为新的诊断和治疗策略提供了基础。
Metabolic Reprogramming by Engineered Probiotics Potentiates Tumor Chemodynamic Immunotherapy.
工程化细菌通过先天免疫原性和局部治疗递送,有望重塑免疫抑制性肿瘤微环境。
Current status, prospects, and challenges of cell therapy for urological tumors.
细胞治疗已重塑了部分血液系统恶性肿瘤的治疗格局,但其在泌尿系统肿瘤中的作用仍然有限且不均衡。
HDAC10 suppresses anti-tumour immunity by inhibiting ILF3-CXCL9 axis to block CD8(+) T cell infiltration and activation in bladder cancer.
尽管免疫检查点阻断为膀胱癌患者带来了新的希望,但其总体缓解率仍然有限。
Intravesical mesothelin-based CAR T cells targeting MUC16 effectively control bladder cancer in preclinical models.
这些发现共同证实 MUC16 是一个治疗候选靶点,并验证膀胱内给药可作为 T 细胞免疫疗法用于治疗器官局限性膀胱癌的平台。
IL-15 trans-presentation at the innate-adaptive interface: mechanisms and translation in cancer immunotherapy.
持久的抗肿瘤免疫需要固有免疫激活、抗原呈递、淋巴细胞致敏、迁移和效应功能。
Engineered T cell membrane coated nanoparticles reverse thermo-resistance and reprogram tumor microenvironment to synergistically potentiate bladder c
免疫治疗在晚期膀胱癌治疗中取得了突破,但免疫抑制性肿瘤微环境(TME)导致临床结局不理想。
Nano-bionic bacteria armed adoptive macrophage therapy against bladder cancer.
膀胱癌是一种高度恶性的肿瘤,治疗方案有限。
Identification of altered immune landscape at single-cell resolution in NSCLC brain metastasis and its association with poor immune checkpoint inhibit
脑转移是晚期非小细胞肺癌(NSCLC)的常见并发症,导致预后不良并降低免疫检查点抑制剂(ICIs)的疗效。
Case Report: Primed dendritic cell immunotherapy for multiple solid tumors.
在这项回顾性病例系列中,我们描述了五名成人(4名男性,1名女性;
MEMBER ACCOUNT
登录成功会直接打开下一页。